Genmab — December 2024
-
Der ER virkelig mange tåbelige opstød og formålstvivlsomme kommentarer, og har været det længe. Kursen og udviklingen i Genmab aktien er afkoblet fra virkeligheden, og kan lige nu ikke regnes hjem. Uanset hvilke forudsætninger der anvendes. Det er jo nærmest en omvendt “meme” aktie! Manglende CD-38 optrin er for længst indregnet i kursen. Dagens kurs fordrer mange flere negative udfald. Aktien er i et dødvande, rent udviklingsmæssigt (OG det er også løgn, men markedet har blot vedtaget det),
-
Hvis aktien er afkoblet fra virkeligheden, kan det også give en vild tur, når den bliver koblet på igen. Om det er op eller ned, må JNJ vise os. Jeg tror, at aktien er meget påvirket af tech og den blow-off top, der rygtes at være i gang. 2025 bliver året, hvor vi får klarhed over det hele.
-
-
der er en stigende debat om, hvordan sundhedssektoren og store medicinalfirmaer, der ikke integrerer AI i deres processer, kan miste konkurrenceevne. AI har potentiale til at revolutionere forskning, diagnose og behandling, hvilket kan give dem, der omfavner teknologien, en betydelig fordel. Investorer er ofte på udkig efter virksomheder, der innoverer og tilpasser sig nye teknologier, hvilket kan påvirke aktiekurserne i fremtiden. Håber Genmab køre fuld skrue m.h.t at implementere AI
-
Genmab vil udvide AI-afdeling
Hisham Hamadeh, der er global chef for datavidenskab og AI i Genmab, forventer at 2025 bliver et vendepunkt.
(medwatch.dk)
-
ASH24 718 Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study https://ash.confex.com/ash/2024/webprogram/Paper198617.html
-
Tadashi Matsushita, MD, PhD: Reducing Treatment Burden in Hemophilia A - findings from the OLE FRONTIER4 study of Mim8. https://www.hcplive.com/view/matsushita-reducing-treatment-burden-hemophilia-a
-
ASH24 1212 Mim8 Prophylaxis Beyond Bleeding: Investigating Multifaceted, Patient-Reported Outcomes for Hemophilia A in the FRONTIER2 Study https://ash.confex.com/ash/2024/webprogram/Paper198395.html
-
Mim8 Improved Patient Outcomes in Hemophilia A in FRONTIER2 Trial https://www.rarediseaseadvisor.com/news/mim8-improved-patient-outcomes-in-hemophilia-a-in-frontier2-trial/
-
Tri-specific Antibody SAR442257 in RRMM - further development halted
-
This Phase 1 study of SAR'257 showed an anti-tumor response in a small number of pts from the rrMM and rrNHL cohorts. Due to safety concerns, in particular high rates of EBV and CMV reactivation and recurrent episodes of CRS in the higher dose levels, the study was terminated during dose escalation
-
ASH24 T Cells from CLL Patients on Venetoclax Mount Potent Cytotoxic Responses in
Combination with Epcoritamab, a CD20/CD3 Bispecific Antibody https://www.postersessiononline.eu/173580348_eu/congresos/ASH2024/aula/-SUN_3231_ASH2024.pdf https://ashpublications.org/blood/article/144/Supplement 1/3231/533852/T-Cells-from-CLL-Patients-on-Venetoclax-Mount -
further ASH24 presentations /posters via https://www.genmabmedicalaffairs.com/congress?filv1=21
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind